Norgine Announces Closing of Investment from Goldman Sachs Asset Management

15 December 2022

15th December, 2022 – Today, Norgine Europe B.V. (“Norgine”, the “Company”), a leading European specialty pharmaceutical company, announced that the Private Equity business within Goldman Sachs Asset Management has completed its acquisition of a majority stake in the Company. The deal closure is a key milestone in Norgine’s history, following over 110 years of family ownership by the Stein Family (who will continue to own a significant stake in the Company). With Goldman Sachs Asset Management as its key partner, Norgine is strongly positioned to deliver on its mission of bringing transformative medicines to market while purposefully putting patients at the heart of its strategy. The Company is focused on growth through advancing its existing portfolio of leading brands, developing and commercializing innovative pipeline products, and leveraging the Norgine platform through business development initiatives.

Norgine has focused on building its fully integrated platform across Europe, Australia and New Zealand for more than 35 years and has grown consistently over that time. Today Norgine generates more than €500 million of sales annually. Its portfolio includes the iconic MOVICOL® brand with 25+ years’ heritage, a growing roster of promoted prescription products, and a portfolio of innovative pipeline products across multiple therapeutic areas.

Norgine serves as a true specialty pharma platform, with a proven track record of developing, acquiring, and in-licensing assets while leveraging its integrated operations, which include a pan-European infrastructure and strong regulatory, market access, and launch capabilities.

Christopher Bath, Chief Executive Officer of Norgine, shared: “I am pleased to see the successful completion of this transformational transaction and to commence work in earnest with the Goldman Sachs Asset Management team. I firmly believe that Norgine’s differentiated capabilities, unique product offering, and strong collaboration with our majority shareholder Goldman Sachs Asset Management will allow us to realize the true potential of our fully integrated pharmaceutical platform for the benefit of patients across Europe, Australia, and New Zealand. I look forward to leveraging the global Goldman Sachs network and its significant pharma and consumer healthcare investment expertise. It is an exciting time to be a part of this great company!”

 

About Norgine
Norgine is a European specialty pharmaceutical company that has strived to deliver innovative medicines to patients for over a century. The Company’s extensive European experience, fully integrated infrastructure, and exceptional partnership approach allow it to quickly apply creative solutions to bring patients life-changing medicines that they may not otherwise be able to access. Norgine is proud to have helped 24 million patients around the world in 2021 and generated €505 million in net product sales, representing growth of 10% over 2020.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand, and employs over 1,500 people.

Norgine and the sail logo are trademarks of the Norgine group of companies.

 

About Goldman Sachs Asset Management Private Equity
Bringing together traditional and alternative investments, Goldman Sachs Asset Management provides clients around the world with a dedicated partnership and focus on long-term performance. As the primary investing area within Goldman Sachs (NYSE: GS), we deliver investment and advisory services for the world’s leading institutions, financial advisors and individuals, drawing from our deeply connected global network and tailored expert insights, across every region and market—overseeing more than $2 trillion in assets under supervision worldwide as of September 30, 2022. Driven by a passion for our clients’ performance, we seek to build long-term relationships based on conviction, sustainable outcomes, and shared success over time. Goldman Sachs Asset Management invests in the full spectrum of alternatives, including private equity, growth equity, private credit, real estate and infrastructure. Established in 1986, the Private Equity business within Goldman Sachs Asset Management has invested over $75 billion since inception. We combine our global network of relationships, our unique insight across markets, industries and regions, and the worldwide resources of Goldman Sachs to build businesses and accelerate value creation across our portfolios. Follow us on LinkedIn.

 

Norgine Media Contact
Eleni Fistikaki
contact@norgine.com
T +44 (0) 1895 826 227

Norgine
Cookie Policy

Last update: 1 August 2023

What are cookies?

Cookies are small data files that websites download to a user’s computer, phone or tablet. Most web browsers automatically accept cookies. They help website providers, for example, to recognise a user that has visited a website previously. Further details on the cookies used on this Website and their purposes are set out below.

  • Helping you navigate the Website in the most easy way possible
  • Assisting in registering for our events, login and your ability to provide feedback
  • Analysing site usage (how many users visited a specific page for example)
  • Analysing the use of our products, services or applications
  • Assisting with our promotional and marketing efforts (including behavioural advertising)
  • Offering content of third parties (such as social media content)

Detailed information about each cookie can be found in the appropriate cookie category section of the banner as well as in the section below.

 

Cookie Category Description

STRICTLY NECESSARY COOKIES

The strictly necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You may be able to decline these cookies through your browser, but necessary parts of the site will not then work. These cookies do not store any personally identifiable information.

 

Detailed list of Strictly Necessary Cookies

 

FUNCTIONAL COOKIES

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

 

Detailed list of Functional Cookies

 

PERFORMANCE COOKIES

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.

 

Detailed list of Performance Cookies

 

MARKETING COOKIES

These cookies are used to track our visitors’ browsing habits. They can be used to build up a profile of search and/or browsing history for every visitor. Identifiable or unique data is collected to show relevant/personalized marketing content to each user. The information that uniquely identifies users’ browsers and internet devices is used to display targeted advertising and/or share this data with third parties for the same purpose.

 

Detailed list of Marketing Cookies

 

 

Refusing cookies

You do not have to accept cookies, but without accepting them you may experience reduced Site functionality. You can manage your preferences regarding cookies and other tracking technologies and revoke your consent in the banner. You can withdraw your consent at any time. If you would like more information about deleting, disabling and blocking cookies, please visit the website: https://knowcookies.com and check the “manage cookies” and “webmasters guide” sections.

 

Updating our Cookie Policy

There is a possibility that we will update our cookie policy on this website in accordance with legal and technical requirements, therefore we recommend that you read this policy occasionally so that you are adequately informed about how and for what we use cookies.

 

Contact

If you have any questions about this Cookie Policy or the collection, processing and disclosure of your personal data and your data protection rights, please see our Privacy Policy.